Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 4 | 2021 | 457 | 0.740 |
Why?
|
| Cystic Fibrosis | 4 | 2024 | 268 | 0.680 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2020 | 17 | 0.650 |
Why?
|
| Sildenafil Citrate | 2 | 2020 | 56 | 0.280 |
Why?
|
| Lipase | 1 | 2006 | 91 | 0.230 |
Why?
|
| Glucose Tolerance Test | 1 | 2024 | 198 | 0.200 |
Why?
|
| Colon | 1 | 2006 | 373 | 0.190 |
Why?
|
| Phenylpropionates | 1 | 2020 | 2 | 0.170 |
Why?
|
| Iloprost | 1 | 2020 | 5 | 0.160 |
Why?
|
| Tadalafil | 1 | 2020 | 4 | 0.160 |
Why?
|
| Receptors, Endothelin | 1 | 2020 | 9 | 0.160 |
Why?
|
| Epoprostenol | 1 | 2020 | 33 | 0.160 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2020 | 34 | 0.160 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 107 | 0.160 |
Why?
|
| Pyridazines | 1 | 2020 | 49 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2024 | 645 | 0.160 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 235 | 0.150 |
Why?
|
| Mass Screening | 1 | 2024 | 822 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2020 | 296 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2020 | 446 | 0.130 |
Why?
|
| Lung Transplantation | 1 | 2022 | 363 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 889 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2026 | 2406 | 0.120 |
Why?
|
| Infant | 5 | 2026 | 13352 | 0.110 |
Why?
|
| Phenotype | 2 | 2026 | 4497 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 197 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 3436 | 0.110 |
Why?
|
| Hypotension | 1 | 2016 | 187 | 0.100 |
Why?
|
| Balloon Occlusion | 1 | 2013 | 48 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2026 | 15110 | 0.090 |
Why?
|
| Child | 6 | 2026 | 26341 | 0.090 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2013 | 150 | 0.080 |
Why?
|
| Prognosis | 1 | 2020 | 4886 | 0.080 |
Why?
|
| Adolescent | 3 | 2024 | 20987 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8635 | 0.060 |
Why?
|
| Barium Sulfate | 1 | 2006 | 13 | 0.060 |
Why?
|
| Young Adult | 1 | 2020 | 10103 | 0.060 |
Why?
|
| Enema | 1 | 2006 | 45 | 0.060 |
Why?
|
| Humans | 9 | 2026 | 131163 | 0.060 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2006 | 113 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2006 | 221 | 0.060 |
Why?
|
| Fibrosis | 1 | 2006 | 429 | 0.050 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 50 | 0.050 |
Why?
|
| Syndrome | 1 | 2026 | 1155 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17753 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 474 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1618 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2024 | 207 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2026 | 919 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 235 | 0.040 |
Why?
|
| Adult | 1 | 2020 | 31282 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 12936 | 0.040 |
Why?
|
| Male | 5 | 2026 | 64957 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 722 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2024 | 1106 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2016 | 29 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 173 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 531 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 732 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1118 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1535 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 711 | 0.030 |
Why?
|
| Female | 4 | 2026 | 70963 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2013 | 76 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2013 | 158 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 161 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2016 | 810 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 414 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 501 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 548 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1216 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3359 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2013 | 630 | 0.020 |
Why?
|
| Risk Factors | 1 | 2022 | 11074 | 0.020 |
Why?
|
| United States | 1 | 2022 | 12072 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 3061 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 5196 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 3711 | 0.010 |
Why?
|